In addition, once-daily dosing with REVOLADE leads to long-term control,1 without the fear of developing neutralising antibodies.2-4Review the long-term efficacy data in ITP
1. REVOLADE Summary of Product Characteristics. February 2019. 2. Lum SH, Grainger JD. Eltrombopag for the treatment of aplastic anemia: current perspectives. Drug Des Devel Ther. 2016;10:2833-2843. 3. Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013;98(1):10-23. 4. Cheng G. Eltrombopag, a thrombopoietin-receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile. Ther Adv Hematol. 2012;3(3):155-164.